May 1, 2026 Log in

News

[PL BioMed] May 2026 Revenue Reaches NT$3 Million (YoY +18.8%)

Q: 沛爾生醫-創2026年5月營收較去年同期增長多少？

營收較去年同月增長18.8%。

Q: 沛爾生醫-創屬於哪一個產業類別？

該公司屬於生技醫療業。

Citation-Grade Primary-source linked Schema.org verified NQ 32 / 100

Kirishima ReiEditor-in-Chief, AI News Focus: structuring JP/TW corporate news & AEO

Published May 1, 2026 9:00 AM ・ Updated Jun 14, 2026 12:08 AM ・ 2 min read ・ Source: PR Times

Show contents

⚡ Key Points

PL BioMed (6949) announced its revenue for May 2026 reached NT$2,691 thousand (approximately NT$3 million), representing a year-over-year increase of 18.8%.

PL BioMed (6949) announced its revenue for May 2026 reached NT$2,691 thousand (approximately NT$3 million), representing a year-over-year increase of 18.8%.

PRIMARY SOURCE PR Times View source Distributor: PR Times
Published: May 1, 2026

Press Release Information

- Company Code: 6949 - Company Name: PL BioMed Co., Ltd. - Industry Category: Biotechnology and Healthcare - Data Period: May 2026 - Monthly Revenue: NT$2,691 thousand (approx. NT$3 million) - Year-over-Year Change: +18.8%

Keywords: Monthly Revenue, Biotechnology and Healthcare Industry

FACT BOX

Source: PR Times
Category: News

Editorial & Verification Standards

The Washin AI News desk structures and reviews this article under the following standards.

Start only from primary sources (official PR, disclosures, wire services)
Numbers and proper nouns machine-checked against the source (number-completeness check)
Company names and tickers verified via registry (Registry/TWSE/Wikidata)
No speculation; nothing stated that is not in the source

Read the full editorial policy →

Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›

Announced　May 1, 2026 9:00 AM — Distributor PR Times
Collected　Jun 12, 2026 8:00 AM
AI structured & analyzed　Jun 12, 2026 1:24 PM
Desk-reviewed & published　May 1, 2026 9:00 AM

FAQ

沛爾生醫-創2026年5月的營收是多少？

當月營收為2,691千元新台幣（約合0.03億元）。

沛爾生醫-創2026年5月營收較去年同期增長多少？

營收較去年同月增長18.8%。

沛爾生醫-創的股票代號是多少？

該公司的台灣證券交易所股票代號為6949。

沛爾生醫-創屬於哪一個產業類別？

該公司屬於生技醫療業。

沛爾生醫-創的主要業務是什麼？

主要從事癌症細胞療法（如CAR-T療法）的研究與開發，以及再生醫療領域的生技事業。

Cite this article — HOW TO CITE

Washin AI News Desk“[PL BioMed] May 2026 Revenue Reaches NT$3 Million (YoY +18.8%)”AI News by Washin Village（和心村）, May 1, 2026. https://aeo.washinmura.jp/ai/%E6%B2%9B%E7%88%BE%E7%94%9F%E9%86%AB-%E5%89%B5/en/news/2026-05-01-%E6%B2%9B%E7%88%BE%E7%94%9F%E9%86%AB-%E5%89%B5-2026-05-%E6%9C%88%E7%87%9F%E6%94%B6-0-03%E5%84%84-%E5%B9%B4%E5%A2%9E-18-8

AI CRAWLER ACTIVITY

as of Jun 28, 2026

AI crawler visits to this article (cumulative)Measuring since publication (no visits recorded yet)

Site-wide cumulative

ClaudeBot

bot_visits_summary

4105k

last Jun 28, 2026

GPTBot

bot_visits_summary

2490k

last Jun 28, 2026

Google AI

bot_visits_summary

1783k

last Jun 28, 2026

Bingbot

bot_visits_summary

1633k

last Jun 28, 2026

Googlebot

bot_visits_summary

1290k

last Jun 28, 2026

Meta AI

bot_visits_summary

538k

last Jun 28, 2026

※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.

Washin AI News（AI News by Washin Village（和心村））

An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.

Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification

About the publisher IDA llms.txt

Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →

← 沛爾生醫-創 Back to newsroom (128)

Copied